2Neumann M,Sampathu D, Kwong L,et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateralsclerosis[J]. Science, 2006,314: 130-133.
3Bigio EH, Wu JY, Deng HX, et al. Inclusions in frontotemporallobar degeneration with TDP-43 proteinopathy ( FTLD-TDP) andamyotrophic lateral sclerosis ( ALS),but not FTLD with FUSproteinopathy (FTLD-FUS),have properties of amyloid [J]. ActaNeuropathol, 2013, 125:463465.
4Arai T, Mackenzie IR, Hasegawa M, et al. Phosphorylated TDP-43 in Alzheimer ’ s disease and dementia with Lewy bodies [J].Acta Neuropathol, 2009,117:125-136.
5Wilson AC, Dugger BN, Dickson DW, et al. TDP-43 in agingand Alzheimer ’ s disease-a review [J]. Int J Clin Exp Pathol,2011,4:147-155.
6Buratti E, Derk T, Zuccato E, et al. Nuclear factor TDP-43 andSR proteins promote in vitro and in vivo CFTR exon 9 skipping[J]. EMBO J, 2001, 20:1774-1784.
7Buratti E, Baralle FE. Characterization and functionalimplications of the RNA binding properties of nuclear factor TDP-43 ,a novel splicing regulator of CFTR exon 9[J]. J Biol Chem,2001, 276:36337-36343.
8Bhardwaj A, Myers MP, Buratti E, et al. Characterizing TDP-43interaction with its RNA targets [J]. Nucleic Acids Res, 2013 ,41:5062-5074.
9Polymenidou M,Lagier-Tourenne C,Hutt KR,et al. Long pre-mRNA depletion and RNA missplicing contribute to neuronalvulnerability from loss of TDP-43 [J]. Nat Neurosci,2011,14:459468.
10Ihara R, Matsukawa K, Nagata Y, et al. RNA binding mediatesneurotoxicity in the transgenic Drosophila model of TDP-43proteinopathy [J]. Hum Mol Genet, 2013 , 22 :4474-4484.
